India Olmesartan Market to grow at a steady rate During the Forecast Period
Growing prevalence of hypertension
is expected to drive the growth of India Olmesartan market.
According to
TechSci Research report, “India Olmesartan Market By Dose (10 mg, 20 mg,
40 mg, Others), By Source (In-house v/s Contract Manufacturing Organizations),
By Distribution Channel (Online v/s Offline), By Application (High Blood
Pressure, Heart Failure, Diabetic Kidney Disease Others), By End User (Adult
v/s Pediatric), By Company, By Region, Forecast & Opportunities, FY2026”, the India Olmesartan market is expected to grow at a steady
rate during the forecast period for the treatment of essential hypertension. Olmesartan
belongs to a class of drugs called angiotensin receptor blockers (ARBs). It generally
relaxes the blood vessels so that blood can flow more easily. Olmesartan is
also used to treat heart failure as well as diabetic nephropathy. This in turn is expected to fuel the market
growth through FY2026. However, side-effects associated with drug consumption
such as feeling dizzy, headache or flu-like symptoms, or pain in your back,
bones or joints, feeling sick (nausea), stomach ache or indigestion, diarrhea, swollen
feet, ankles or legs, urinary tract infection (UTI) can restrict the market
growth over the next few years. Moreover, in certain cases itching, a rash, or
lumps on skin, or tiny red spots under the skin are also observed. This can
further reduce the usage and application of the drug thereby hindering the
market growth during the forecast period.
Browse XX market data Tables and XX Figures spread
through XXX Pages and an in-depth TOC on" India Olmesartan Market"
https://www.techsciresearch.com/report/india-olmesartan-market/5149.html
The India
Olmesartan market is segmented based on dose, source, distribution channel,
application, end user, company, and region. Based on application, the market
can be fragmented into high blood pressure, heart failure, diabetic kidney
disease, others. The high blood pressure segment is expected to dominate the
market in the forthcoming years on account of rising count of patients having high
blood pressure. Based on source, the market can be categorized into in-house
v/s contract manufacturing organizations. The in-house segment dominated the
market until 2017 as most of the leading companies focus on in house production.
In terms of dose, the market is split into 10 mg, 20 mg, 40 mg, Others. Among
them, 20 mg dose segment is projected to dominate the market in the next 5
years as 20 mg dose is the recommended starting dose of Olmesartan for adults
and children.
Glenmark
Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Cadila Pharmaceuticals
Ltd., Sun Pharmaceuticals Industries Ltd., Unichem Laboratories Ltd., Cipla
Ltd., Torrent Pharmaceuticals Ltd., Lupin Laboratories Ltd. (Pinnacle), Abbott
Healthcare Pvt. Ltd., Morepen Laboratories Ltd and others are some of the
leading players operating in India Olmesartan market. Companies operating in
the market are using organic strategies such as product launches, new
technologies, pharma licensing deals, mergers and acquisitions, research
collaborations to boost their share and increase their geographic reach.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5149
Customers can
also request for 10% free customization on this report.
“India Olmesartan market is
expected to witness growth during the forecast period as it is used to treat
high blood pressure (hypertension) and therefore helps to prevent strokes,
heart attacks, and kidney problems in an individual. Olmesartan also affects
the renin-angiotensin aldosterone system (RAAS), which performs an essential
part in haemostasis and regulation of kidney, vascular, and cardiac functions. This
is further expected to create lucrative opportunities for the market growth of “India
Olmesartan market over the next five years.” said Mr. Karan Chechi, Research
Director with TechSci Research, a research based India management consulting
firm.
“India Olmesartan Market By Dose (10 mg, 20
mg, 40 mg, Others), By Source (In-house v/s Contract Manufacturing
Organizations), By Distribution Channel (Online v/s Offline), By Application
(High Blood Pressure, Heart Failure, Diabetic Kidney Disease Others), By End
User (Adult v/s Pediatric), By Company, By Region, Forecast &
Opportunities, FY2026”, has evaluated
the future growth potential of India Olmesartan market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges and
opportunities in India Olmesartan market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]